Toyama's flu drug progresses in US as peramivir filed for paediatric use in Japan
This article was originally published in Scrip
Toyama Chemical has begun a Phase II clinical trial in the US with its novel oral antiviral agent favipiravir (T-705), becoming the latest Japanese firm to take forward a new treatment option for flu infections.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.